Ann: Shareholder Newsletter, page-36

I'm a long term holder ~11 years . Became interested in drug delivery technology over 10 years ago as I could see a lot of big pharma patents were running out. Being able to extend the life drug with new delivery technology and collaboration/buy out, I thought, was a strategy big pharma would use.

I been quite impressed with the update and interviews. I increased my holdings by ~50% yesterday.

Viraleze looks to be a solid product. Not only for SARS-CoV-2, but the potentially multiple strains of influenza and RSV (and maybe other resp viruses). As the lockdowns were lifted our Emergency Departments were inundated with RSV paediatric presentations.

I see the recommended use of Viraleze is for >12yo. If safety was verified for paediatric use it would be a game changer (i can't see why it wouldn't be safe). We have no preventative measures apart from good hygiene practices. A few good sprays as a drop my children off to day care. I'd be using it day if my kids had a cold. Imagine reduced sick days/increased productivity of a work force.

I don't wont to understate the importance of prevention of Covid but this could be useful on so many levels